Appendix
Clinical Trials
An open label, multicenter study, evaluating the safety and imaging characteristics
of 18F-AV-1451 in cognitively healthy volunteers, subjects with Mild Cognitive
Impairment, and subjects with Alzheimer’s Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group
Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects
with Early Alzheimer’s Disease
A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451
PET Imaging and Post-Mortem Assessment of Tau Pathology
A Pilot Study: Reducing Post-Operative Delirium and Other Complications
Associated with Cognitive Impairment in Orthopedic Surgery
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled,
Parallel-Group, Efficacy And Safety Study Of Crenezumab In Patients With
Prodromal To Mild Alzheimer’s Disease
A 15-Week, Phase 2, Double Blind, Randomized, Placebo-Controlled, Dose
Ranging Study To Investigate The Efficacy, Safety And Tolerability of
PF-06649751 In Subjects With Motor Fluctuations Due To Parkinson’s Disease
An open label, multicenter study evaluating the imaging characteristics
of a follow up 18F-AV-1451 scan in subjects that participated in the confirmatory
cohort of 18F-AV-1451-A05 (AVID A18)
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group,
MulticenterStudy Investigating the Efficacy and Safety of JNJ-54861911
in Subjects who areAsymptomatic At Risk for Developing Alzheimer’s Dementia
A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability
of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with
Parkinson’s Disease Experiencing End of Dose “Wearing-Off”
Providence Cognitive Decline Intervention Trial
Thromboaspiration of Downstream and New Territory Emboli Using the 3Max
catheter after Mechanical Thrombectomy of Large Vessel Occlusions
